1-5 of 5
Matthew V. Lorenzi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Dirk Brehmer, Lijs Beke, Tongfei Wu, Hillary J. Millar, Christopher Moy, Weimei Sun, Geert Mannens, Vineet Pande, An Boeckx, Erika van Heerde, Thomas Nys, Emmanuel M. Gustin, Bie Verbist, Longen Zhou, Yue Fan, Vipul Bhargava, Pegah Safabakhsh, Petra Vinken, Tinne Verhulst, Angelique Gilbert, Sumit Rai, Timothy A. Graubert, Friederike Pastore, Danilo Fiore, Junchen Gu, Amy Johnson, Ulrike Philippar, Barbara Morschhäuser, David Walker, Desiree De Lange, Vikki Keersmaekers, Marcel Viellevoye, Gaston Diels, Wim Schepens, Jan Willem Thuring, Lieven Meerpoel, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2317–2328.
https://doi.org/10.1158/1535-7163.MCT-21-0367
Published: 01 December 2021
View article titled, Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
Open the PDF for Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity in another window
Journal Articles

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, Sheri L. Moores
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (10): 2044–2056.
https://doi.org/10.1158/1535-7163.MCT-20-0071
Published: 02 October 2020
View article titled, Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Open the PDF for Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis in another window
Includes: Multimedia, Supplementary data
Journal Articles

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph C. Portale, Ademi Santiago-Walker, Christopher H. Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng R. Luo, John D. Alvarez, Matthew V. Lorenzi, Suso J. Platero
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (8): 1717–1726.
https://doi.org/10.1158/1535-7163.MCT-16-0518
Published: 02 August 2017
View article titled, Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
Open the PDF for Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib in another window
Includes: Supplementary data
Journal Articles

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy P.S. Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Tinne Verhulst, Caroline Paulussen, Kelly Van De Ven, Peter King, Eddy Freyne, David C. Rees, Matthew Squires, Gordon Saxty, Martin Page, Christopher W. Murray, Ron Gilissen, George Ward, Neil T. Thompson, David R. Newell, Na Cheng, Liang Xie, Jennifer Yang, Suso J. Platero, Jayaprakash D. Karkera, Christopher Moy, Patrick Angibaud, Sylvie Laquerre, Matthew V. Lorenzi
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (6): 1010–1020.
https://doi.org/10.1158/1535-7163.MCT-16-0589
Published: 01 June 2017
View article titled, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Open the PDF for Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor in another window
Includes: Supplementary data
Journal Articles

Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics

Kristen A. Kellar, Matthew V. Lorenzi, Ching Ping Ho, Dan You, Mei-Li Wen, Rolf P. Ryseck, Simone Oppenheimer, Brian E. Fink, Gregory D. Vite, Bruce R. Rowley, Chiang Yu, David K. Bol, Francis Y. Lee, Tai W. Wong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (6): 1571–1576.
https://doi.org/10.1158/1535-7163.MCT-06-0078
Published: 03 July 2006
View article titled, Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics
Open the PDF for Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics in another window